16:15 às 17:15 - Sessão 3 - Best of SABCS 2017 - Parte 2

16:35 às 16:45 - Abstract GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) study